慢性心力衰竭患者血浆血管抑制因子2的研究

Plasma vasostatin-2 levels in chronic heart failure patients

目的研究慢性心力衰竭(CHF)患者血浆血管抑制因子2(VS2)水平及其潜在临床意义。方法参照Framingham临床心力衰竭的诊断标准,入选216例CHF患者为研究组,其中无或轻度CHF症状93例,中重度CHF症状123例;缺血性心脏病99例,非缺血性心脏病117例。选择同期171例体检健康者为对照组。用ELISA法测定血浆VS2水平。结果研究组血浆VS2水平显著低于对照组[0.805(0.547,1.187)μg/L vs 0.983(0.510,1.783)μg/L,P=0.011]。无或轻度CHF症状与中重度CHF症状者VS2水平比较无显著差异(P=0.908),缺血性心脏病与非缺血性心脏病患者VS2水平比较无显著差异(P=0.409)。123例中重度CHF症状患者VS2水平与心率呈负相关(r=-0.198,P=0.028)。结论 CHF患者血浆VS2水平降低,VS2与心力衰竭程度无关。

Objective To study the plasma vasostatin-2 levels in chronic heart failure （CHF） pa- tients and their potential clinical significance. Methods Two hundred and sixteen CHF patients served as an experimental group and 171 healthy subjects undergoing physical examination served as a control group in this study. Their plasma vasostatin-2 levels were measured by ELISA. Re- sults The plasma vasostatin-2 levels were significantly lower in experimental group than in con- trol group [0. 805（0. 547,1. 187）μg/L vs 0. 983（0. 510,1. 783）μg/L,P=0. 011]. No significant difference was found in plasma vasostatin-2 levels between the patients without or with mild heart failure and those with moderate heart failure,and between the patients with ischemic heart disease and those without ischemic heart failure （P = 0. 908, P = 0. 409）. The plasma vasostatin-2 levels were negatively related the heart rate in the 123 patients with moderate-severe heart failure （r= -0. 198,P=0. 028）. Conclusion The plasma vasostatin-2 levels are low in CHF patients, whichis not related with the severity of heart failure.